Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes
Authors:
- 23 October 2020
- journal article
- research article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 62 (6) , 833-838
Abstract
Rationale: Despite the importance of the Glucagon receptor (GCGR) in disease and in pharmaceutical drug development, there is a lack of specific and sensitive biomarkers of its activation in human. The Positron Emission Tomography (PET) radioligand 68Ga-DO3A-VS-Tuna-2 (68Ga-Tuna-2) was developed to yield a non-invasive imaging marker for GCGR target distribution and drug target engagement in humans. Methods: The biodistribution and dosimetry of 68Ga-Tuna-2 was assessed by PET/Computed Tomography (CT) in n = 13 individuals with Type 2 Diabetes (T2D) as part of a clinical study assessing the occupancy of dual GCGR/Glucagon Like Peptide-1 Receptor (GLP-1R) agonist SAR425899. Binding of 68Ga-Tuna-2 in liver and reference tissues was evaluated and correlated to biometrics (e.g. weight or BMI) or other biomarkers (e.g. plasma glucagon levels). Results: 68Ga-Tuna-2 binding was seen primarily in the liver, which is in line with the strong expression of GCGR on hepatocytes. Kidney demonstrated high excretion related retention, while all other tissue demonstrated rapid washout. The Standardized Uptake Value (SUV)55min uptake endpoint was sensitive to endogenous levels of glucagon. 68Ga-Tuna-2 exhibited a safe dosimetry profile, and no adverse events after intravenous administration. Conclusion: 68Ga-Tuna-2 can be used for safe and accurate assessment of the GCGR in human. It may serve as an important tool in understanding the in vivo pharmacology of novel drugs engaging the GCGR.Keywords
This publication has 13 references indexed in Scilit:
- Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primatesScientific Reports, 2019
- First-in-class positron emission tomography tracer for the glucagon receptorEJNMMI Research, 2019
- A novel dual glucagon‐like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo‐controlled first‐in‐human and first‐in‐patient trialsDiabetes, Obesity and Metabolism, 2018
- Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic MonkeysEndocrinology, 2018
- Running on mixed fuel‐dual agonistic approach of GLP‐1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non‐human primatesDiabetes, Obesity and Metabolism, 2018
- GLP-1/glucagon receptor co-agonism for treatment of obesityDiabetologia, 2017
- Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor AgonistsJournal of Medicinal Chemistry, 2017
- The New Biology and Pharmacology of GlucagonPhysiological Reviews, 2017
- Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in MiceDiabetes, 2009
- A new glucagon and GLP-1 co-agonist eliminates obesity in rodentsNature Chemical Biology, 2009